On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: ChinaCache International Holdings Ltd. (NASDAQ:CCIH), Herbalife Ltd. (NYSE:HLF), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Olin Corp. (NYSE:OLN)
ChinaCache International Holdings Ltd. (NASDAQ:CCIH), with shares gained 18.12%, closed at $10.30.
Herbalife Ltd. (NYSE:HLF), with shares jumped 3.13%, settled at $43.17.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), with shares climbed 14.64%, and closed at $7.75.
Olin Corp. (NYSE:OLN), surged 14.01%, and closed at $31, hitting new 52-week high of $34.34.
Latest NEWS regarding these Stocks are depicted underneath:
ChinaCache International Holdings Ltd. (NASDAQ:CCIH)
ChinaCache International Holdings Ltd. (CCIH), declared its unaudited condensed merged financial results for the fourth quarter and full fiscal year ended December 31, 2014.
Highlights for the Fourth Quarter of 2014:
- Net proceeds in the fourth quarter were RMB338.9 million (US$54.6 million) as contrast with RMB339.4 million in the fourth quarter of 2013.
- Gross profit in the fourth quarter was RMB101.7 million (US$16.4 million), reflecting a 30.0% gross profit margin in the fourth quarter.
- Financial results in the fourth quarter were influenced by a one-time RMB32.5 million (US$5.2 million) non-cash bad debt provision related to a single customer from previous years.
- Not including this one-time non-cash bad debt provision of RMB32.5 million (US$5.2 million), fourth-quarter adjusted EBITDA (non-GAAP) was RMB44.7 million (US$7.2 million) and fourth-quarter adjusted net revenue (non-GAAP) was RMB 15.7 million (US$2.5 million).
- Not including this one-time non-cash bad debt provision of RMB32.5 million (US$5.2 million),adjusted net revenue per diluted ADS (non-GAAP) was RMB0.59 (US$0.09) in the fourth quarter of 2014 as contrast to an adjusted net loss per ADS of RMB0.31 in the fourth quarter of 2013.
Highlights for the Full Year 2014:
- Net proceeds in 2014 reached a record high of RMB1,384.3 million (US$223.1 million), representing a 25.5% raise over the previous year.
- Gross profit in 2014 was RMB417.7 million (US$67.3 million), up 20.5% from 2013.
- Not including the one-time non-cash bad debt provision of RMB32.5 million (US$5.2 million) from the fourth quarter 2014, the adjusted EBITDA (non-GAAP) in 2014 was RMB135.5 million (US$21.8 million) and adjusted net revenue (non-GAAP) in 2014 was RMB38.9 million (US$6.3 million).
- Not including this one-time non-cash bad debt provision of RMB32.5 million (US$5.2 million),adjusted net revenue per diluted ADS (non-GAAP) was RMB1.46 (US$0.24) for the full-year 2014 as contrast to an adjusted net loss per ADS of RMB0.79 for the full-year 2013.
ChinaCache International Holdings Ltd., through its auxiliaries, provides content and application delivery services in the People’s Republic of China. The corporation offers a portfolio of services and solutions to businesses, government agencies, and other enterprises to enhance the reliability and scalability of their online services and applications.
Herbalife Ltd. (NYSE:HLF)
Formerly on March 25, More than 4,000 Southern California residents—Herbalife members and other supporters—are gathering at Grand Park recently in front of Los Angeles City Hall to tell local legislators about their experiences with Los Angeles-based Herbalife Ltd. (HLF), and show their support for the global nutrition corporation.
The rally comes as Herbalife members from across Southern California—from San Diego to San Bernardino—visit Los Angeles City Hall to meet with key Los Angeles City Hall leaders and share how Herbalife is assisting them lead healthier, more active lives, and offering those who are interested an opportunity to earn full-time or supplemental revenue selling the corporation’s nutrition products.
Herbalife has a strong presence and makes a noteworthy economic contribution in California. It presently has six manufacturing and distribution facilities, and there are 1,500 employees and more than 120,000 members residing in the state. It also paid $28 million in California sales tax in 2014. Herbalife was founded in Los Angeles in 1980, with headquarters at L.A. Live since the complex opened in 2008.
Herbalife Ltd., a nutrition corporation, develops and sells weight administration, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products. The corporation offers science-based products in four principal categories, counting weight administration; targeted nutrition; energy, sports, and fitness; and outer nutrition.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. (CNAT), declared top-line results from the corporation’s Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), counting the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, showing a statistically noteworthy(p<0.05) reduction in alanine amino transferase (ALT) in patients treated for 28 days with emricasan at 25 mg twice per day dosing contrast to patients in the placebo control group. Reductions from baseline in ALT at Day 28 of about 39% in the emricasan treatment arm and about 14% in the placebo arm were similar to results observed in previous trials. Elevated baseline levels of three key serum biomarkers — caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18, and caspase 3/7 — also showed statistically noteworthy reductions from baseline in emricasan-treated patients at Day 28. The baseline elevation in cCK18 confirmed that the underlying targets of emricasan’s mechanism, apoptosis and inflammation, which are believed to drive liver disease progression, were engaged in the NAFLD/NASH patients in this trial. A reduction from baseline in cCK18 at Day 28 of about 30% in the emricasan treatment arm and an raise from baseline of about 4% in the placebo arm were similar to results observed in previous trials. The reduction in serum cCK18 levels demonstrated that emricasan can effectively reduce inflammation and elevated levels of apoptosis in NAFLD/NASH patients. These results were consistent with data obtained from the corporation’s previous clinical trials in other liver disease patient populations.
Emricasan was safe and well tolerated in the NAFLD/NASH trial, with no dose-limiting toxicities and no drug-related serious adverse events. Treatment with emricasan also had no adverse effects on lipid levels or insulin sensitivity, important safety assessments in NAFLD/NASH patients who are at risk for cardiovascular disease. Detailed results from the NAFLD/NASH trial will be presented in a late-breaker poster at The International Liver Congress(TM) 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26, 2015.
“With these results from the NAFLD/NASH trial, we have confirmed that the optimal dose of emricasan is consistent across different etiologies,” said Conatus co-founder, President and Chief Executive Officer, Steven J. Mento, Ph.D., “and strengthened our belief that inhibiting excessive apoptosis and inflammation will be therapeutic in patients whose liver damage is associated with NASH.”
Conatus Pharmaceuticals Inc., a biotechnology corporation, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products comprise Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease.
Olin Corp. (NYSE:OLN)
Olin Corp. (OLN), and The Dow Chemical Corporation (DOW), declared that the boards of directors of both companies unanimously approved a definitive contract under which Dow will separate a noteworthy portion of its chlorine value chain and merge that new entity with Olin in a transaction that will create an industry leader with proceeds approaching $7 billion. The transaction has a tax efficient consideration of $5 billion, and a taxable equivalent value of $8 billion to Dow and Dow shareholders. It is highly complementary to the planned objectives of both companies, with noteworthy potential to enhance value for both Dow and Olin shareholders, and create substantial benefits for customers.
The terms of the contract call for Dow to separate its U.S. Gulf Coast Chlor-Alkali and Vinyl, Global Chlorinated Organics and Global Epoxy businesses, and then merge these businesses with Olin in a Reverse Morris Trust transaction. The merger will result in Dow shareholders receiving about 50.5 percent of the shares of Olin, with existing Olin shareholders owning about 49.5 percent.
The transaction is valued at $5 billion, and comprises $2.0 billion of cash and cash equivalents to be paid to Dow; an estimated $2.2 billion in Olin ordinary stock using the Olin stock value as of close on March 25, 2015; and about $800 million of assumption of pension and other liabilities. In addition, by virtue of the joint share ownership, both sets of shareholders will benefit from a minimum of $200 million in projected annual synergies and cost savings.
Olin Corporation manufactures and sells chlor alkali products in the United States and internationally. The corporation operates through three segments: Chlor Alkali Products, Chemical Distribution, and Winchester.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
